Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM0504 vs Semaglutide as Add-on to Metformin in Type 2 Diabetes
NCT07064486Phase 3Active, not recruiting
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Jul 2025
- Primary completion
- Apr 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BGM0504 in type 2 diabetes mellitus (T2DM), sponsored by BrightGene Bio-Medical Technology. Started Jul 2025; status: active, not recruiting.
02
Drugs
BGM0504
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07064486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07064486.